Dec 30, 2025 • MarketBeat
NEUTRAL
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Hold" by Brokerages
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received an average "Hold" rating from fourteen brokerages, with a 12-month consensus target price of $75.10. Despite recent positive financial results, including a Q3 EPS of $1.72 exceeding estimates and a 22.1% year-over-year revenue increase, insiders have sold approximately 85,661 shares. Institutional investors, however, hold a significant 97.8% of the stock, with several large funds increasing their positions.
Dec 29, 2025 • 富途牛牛
SOMEWHAT-BULLISH
Market Still Lacking Some Conviction On Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a P/E ratio of 13.6x, which is lower than the market average in the United States, despite strong past earnings growth and significant forecast future growth. Analysts predict Halozyme's EPS to climb by 22% annually over the next three years, outpacing the broader market's 12% forecast. The lower P/E suggests some investor skepticism about the company's future earnings stability, despite its positive outlook.
Dec 27, 2025 • MarketBeat
NEUTRAL
Voya Investment Management LLC Has $3.39 Million Holdings in Halozyme Therapeutics, Inc. $HALO
Voya Investment Management LLC reduced its stake in Halozyme Therapeutics, Inc. ($HALO) by 60.1% in Q3, now holding 46,250 shares valued at approximately $3.39 million. Other institutional investors have also adjusted their positions in the biopharmaceutical company, which has seen insider selling of 85,661 shares recently. Despite mixed analyst ratings, with a consensus "Hold" and average price target of $75.10, Halozyme beat Q3 earnings and revenue estimates.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BULLISH
Pacer Advisors Inc. Acquires 456,649 Shares of Halozyme Therapeutics, Inc. $HALO
Pacer Advisors Inc. significantly increased its stake in Halozyme Therapeutics (NASDAQ:HALO) by over 2,000%, acquiring 456,649 additional shares to own a total of 478,874 shares, valued at approximately $35.1 million. This move comes as Halozyme exceeded recent quarterly expectations with strong EPS and revenue growth. Despite mixed analyst sentiment, the company's financial performance and institutional interest highlight its position in the biopharmaceutical sector.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BULLISH
Osaic Holdings Inc. Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO
Osaic Holdings Inc. significantly increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 80.9% in the second quarter, now owning 53,448 shares valued at approximately $2.97 million. This move comes as Halozyme Therapeutics reported strong quarterly earnings, beating analyst expectations with an EPS of $1.72 and revenues of $354.3 million. Despite a "Hold" consensus rating from analysts, institutional investors collectively own 97.79% of the company's stock, indicating strong institutional interest.
Dec 25, 2025 • Investing.com
NEUTRAL
Halozyme Therapeutics CEO sells $1.14 million in stock
Halozyme Therapeutics CEO Helen Torley sold 16,569 shares of common stock for approximately $1.14 million and exercised options to purchase an equal number of shares. Additionally, Torley gifted 25,000 shares to charity. The company recently received FDA approval for a new lung cancer treatment, awarded performance-based restricted stock units to the CEO, and appointed a new board member.